Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Cash & Current Investments (2020 - 2025)

Mainz Biomed's Cash & Current Investments history spans 5 years, with the latest figure at $6.2 million for Q4 2024.

  • For Q4 2024, Cash & Current Investments fell 11.81% year-over-year to $6.2 million; the TTM value through Dec 2024 reached $6.2 million, down 11.81%, while the annual FY2024 figure was $6.2 million, 11.81% down from the prior year.
  • Cash & Current Investments for Q4 2024 was $6.2 million at Mainz Biomed, down from $7.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $17.1 million in Q4 2022 and bottomed at $122568.0 in Q4 2020.
  • The 5-year median for Cash & Current Investments is $7.1 million (2023), against an average of $7.9 million.
  • The largest annual shift saw Cash & Current Investments soared 7020.57% in 2021 before it crashed 58.75% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $122568.0 in 2020, then skyrocketed by 7020.57% to $8.7 million in 2021, then skyrocketed by 96.41% to $17.1 million in 2022, then plummeted by 58.75% to $7.1 million in 2023, then dropped by 11.81% to $6.2 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Cash & Current Investments are $6.2 million (Q4 2024), $7.1 million (Q4 2023), and $17.1 million (Q4 2022).